Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 7, 2005, Pages 1075-1081

  Kalambokis, Georgios ^a   Economou, Michalis ^a   Paraskevi, Kosta ^a   Konstantinos, Papadimitriou ^a   Pappas, Christos ^a   Katsaraki, Afroditi ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cirrhosis; Hemodynamics; Sodium excretion; Somatostatin; Terlipressin

Indexed keywords

PLACEBO; SOMATOSTATIN; TERLIPRESSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER FLOWMETRY; DRUG EFFECT; ESOPHAGUS VARICES; FEMALE; HEART OUTPUT; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL;

EID: 21844452200     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03902.x     Document Type: Article

References (41)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
2. Boyer JL, Chatterjee C, Iber FL, Basu AK. Effect of plasma volume expansion on portal hypertension. N. Engl. J. Med. 1966; 275: 750-5.
3. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertensive rats. Hepatology 1992; 15: 323-8.
4. Navarro VJ, Garcia Tsao G. Variceal hemorrhage. Gastrointest. Emerg. 1995; 11: 391-413.
5. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J. Hepatol. 2003; 38: S54-68.
6. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800-9.
7. Garcia-Pagan JC, Escorcell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Semin. Liver Dis. 1999; 19: 427-38.
8. Hussey KP. Vasopressin therapy for upper gastrointestinal tract haemorrhage. Has its efficacy been proven? Arch. Intern. Med. 1985; 145: 1263-7.
9. Jekins SA, Shields R, Davies M et al. A multicentre randomized trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997; 41: 526-33.
10. Lin HC, Yang YY, Hou MC et al. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. Scand. J. Gastroenterol. 2002; 37: 482-7.
11. Moller S, Hansen EF, Becher U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic hemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20: 51-9.
12. Merkel C, Gatta A, Bolognesi M et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig. Dis. Sci. 1988; 33: 1103-9.
13. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
14. Therapondos G, Stanley AJ, Hayes PC. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study. J. Gastroenterol. Hepatol. 2004; 19: 73-7.
15. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J. Hepatol. 1997; 26: 1229-34.
16. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology 1981; 80: 518-25.
17. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am. J. Physiol. 1992; 262: 274-7.
18. Pizcueta MP, Garcia-Pagan JC, Fernandez M, Casamitjana R, Bosch J, Rodes J. Glucagon hinders the effects of somatostatin on portal hypertension. Gastroenterology 1991; 101: 1710-15.
19. Gines A, Salmeron JM, Gines P et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992; 103: 1868-74.
20. Naeije R, Hallemans R, Mols P et al. Effects of vasopressin and somatostatin on hemodynamics and blood gases in patients with liver cirrhosis. Crit. Care Med. 1982; 10: 578-2.
21. Perello A, Escorsell A, Bru C et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999; 30: 1393-7.
22. Iwao T, Toyonaga A, Oho K et al. Value of Doppler ultrasound parameters of portal vein and hepatic artery in the diagnosis of cirrhosis and portal hypertension. Am. J. Gastroenterol. 1997; 26: 305-11.
23. Taurel P, Blanc P, Dauzat M et al. Doppler study of mesenteric, hepatic and portal circulation in alcoholic cirrhosis: Relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology 1998; 28: 932-6.
24. Iwao T, Oho K, Sakai T et al. Noninvasive hemodynamic measurements of superior mesenteric artery in the prediction of portal pressure response to propranolol. J. Hepatol. 1998; 28: 847-55.
25. Kravetz D, Bosch J, Arderiu MT et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am. J. Physiol. 1988; 254: 322-8.
26. Benoit JN, Zimmerman B, Premen AJ, Go VLW, Granger DN. Role of glucagon in the splanchnic hyperemia of chronic portal hypertension. Am. J. Physiol. 1986; 251: 674-7.
27. Pizcueta MP, Casamitjana R, Bosch J, Rodes J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am. J. Physiol. 1990; 258: 191-5.
28. Sonnenberg GE, Keller U, Perruchoud A et al. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology 1981; 80: 526-32.
29. Cirera I, Feu F, Luca A et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double blind hemodynamic investigation. Hepatology 1995; 22: 106-11.
30. Yang YY, Lin HC, Huang YT et al. Adaptive vasodilatory response of octreotide in cirrhotic rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: 117-23.
31. Lin HC, Tsai YT, Lee FY et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992; 103: 229-34.
32. Escorsell A, Bandi JC, Andreu V et al. Desensitization of the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 161-9.
33. Nishida H, Giostra E, Spahr L et al. Acute effects of somatostatin, octreotide or placebo in patients with cirrhosis. A double-blind study. Hepatology 1998; 28: 235 (Abstract).
34. Moller S, Brinch K, Henriksen JH et al. Effect of octreotide on systemic, central, and splanchnic hemodynamics in cirrhosis. J. Hepatol. 1997; 26: 1026-33.
35. Oberti F, Veal N, Kaassis M et al. Hemodynamic effects of terlipressin and octreotide administration alone or in combination in portal hypertensive rats. J. Hepatol. 1998; 29: 103-11.
36. Moreau R, Cailmail S, Valla D, Lebrec D. Hemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats. Aliment. Pharmacol. Ther. 1997; 11: 993-7.
37. Gaudin C, Moreau R, Champigneulle B et al. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995; 15: 236-41.
38. McCormick PA, Chin J, Greeslade L et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995; 21: 1255-60.
39. Hou ZY, Lin CI, Chiu TH et al. Somatostatin effects in isolated human atrial fibers. J. Mol. Cell. Cardiol. 1987; 19: 177-85.
40. Webb SC, Kirikler DM, Hendry WG et al. Electrophysiological actions of somatostatin on the atrioventricular junction in sinus rhythm and reentry tachycardia. Br. Heart J. 1986; 56: 236-41.
41. Gardenas A, Gines P. Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis. Semin. Nephrol. 2001; 21: 308-16.